Physician profile
Jerry J Markar
NPI 1083145320
$4,569.11
in general payments reported to CMS, 2019-2025
15 companies · $21.89 in 2025
The $21.89 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,396 · 2022: $1,966 · 2023: $99.51 · 2024: $85.13 · 2025: $21.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $192 · Education: $14.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $191.66 |
| Education | $14.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,332.92 | 2021-2022 | |
| Nalu Medical, INC. | $373.99 | 2021-2022 | |
| Painteq LLC | $256.90 | 2022 | |
| Nevro Corp. | $158.61 | 2021 | |
| Medtronic, INC. | $100.41 | 2021-2023 | Intellis Adaptivestim |
| Janssen Biotech, INC. | $68.53 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $45.81 | 2023 | Ibsrela |
| Vertos Medical, INC. | $45.62 | 2022 | |
| Relievant Medsystems, INC. | $34.34 | 2022 | |
| Avanos Medical | $31.83 | 2021-2022 | |
| Grt US Holding, INC. | $30.52 | 2021 | |
| Spr Therapeutics, INC | $26.08 | 2023 | Sprint Pns System |
| Tersera Therapeutics LLC | $25.06 | 2022 | |
| Madrigal Pharmaceuticals | $23.62 | 2024 | Resmetirom |
| Celltrion USA INC. | $14.87 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Markar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.